Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eNRGy study of MCLA-128 in advanced solid tumors
NL-OMON54685Phase 2Recruiting
- Sponsor
- Merus
- Start
- Mar 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zenocutuzumab in Nonhematologic neoplasms, Epithelial cancer is not a specific disease name; it is a broad category referring to cancers that arise from epithelial cells. The most common and clinically recognized example is "epithelial ovarian cancer". However, the term alone does not specify a single disease, non-small cell lung cancer (NSCLC) and 1 more (9 arms), sponsored by Merus. Primary endpoints: Safety and tolerability, Antitumor activity and biomarker relationship and 2 more. Started Mar 2015; status: recruiting.
02
Drugs
zenocutuzumab
03
Conditions
Nonhematologic neoplasmsEpithelial cancer is not a specific disease name; it is a broad category referring to cancers that arise from epithelial cells. The most common and clinically recognized example is "epithelial ovarian cancer". However, the term alone does not specify a single disease.non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON54685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54685.